Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.720 +0.060 (+3.60%)
Streaming Delayed Price Updated: 10:06 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 45,578
Open 1.650
Bid (Size) 1.700 (5,500)
Ask (Size) 1.710 (1,200)
Prev. Close 1.660
Today's Range 1.650 - 1.720
52wk Range 0.9400 - 1.919
Shares Outstanding 15,641,611
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights Potent Anti-Measles Results for NV-387 in Proactive Interview
Via Investor Brand Network
Topics Intellectual Property

Performance

YTD
+21.1%
+21.1%
1 Month
+24.6%
+24.6%
3 Month
+8.2%
+8.2%
6 Month
+37.3%
+37.3%
1 Year
+17.0%
+17.0%

More News

Read More
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at PODD 2025 Conference in Boston
Via Investor Brand Network
Topics Intellectual Property
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Strong Antiviral and Lung-Protective Activity of NV-387 Against Measles
Via Investor Brand Network
Topics Intellectual Property
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
Via ACCESS Newswire
A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Featured in Analyst Report Highlighting Dual-Track Clinical Strategy for NV-387
Via Investor Brand Network
Topics Intellectual Property
NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
Via ACCESS Newswire
NanoViricides, Inc. Has Filed its Annual Report
Via ACCESS Newswire
RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at LSX World Congress 2025
Via Investor Brand Network
Topics Intellectual Property
NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
Via ACCESS Newswire
NanoViricides Reports NV-387’s Anti-Inflammatory Effects Could Combat Viral-Induced Cancer Resurgence
Via AB Newswire
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Treatment for Growing Measles Outbreaks
Via Investor Brand Network
Topics Intellectual Property
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Highlights NV-387’s Broad Antiviral Potential and Strategic Value for Pandemic Preparedness
Via Investor Brand Network
Topics Intellectual Property
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
Via ACCESS Newswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Breakthrough Measles Drug Success in Humanized Animal Study
Via Investor Brand Network
Topics Intellectual Property
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides, Inc. (NYSE American: NNVC) Highlights MPox Drug Progress as WHO Extends Global Health Emergency
Via Investor Brand Network
Topics Intellectual Property
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
Via ACCESS Newswire

Frequently Asked Questions

Is NanoViricides, Inc. Common Stock publicly traded?
Yes, NanoViricides, Inc. Common Stock is publicly traded.
What exchange does NanoViricides, Inc. Common Stock trade on?
NanoViricides, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for NanoViricides, Inc. Common Stock?
The ticker symbol for NanoViricides, Inc. Common Stock is NNVC on the New York Stock Exchange
What is the current price of NanoViricides, Inc. Common Stock?
The current price of NanoViricides, Inc. Common Stock is 1.720
When was NanoViricides, Inc. Common Stock last traded?
The last trade of NanoViricides, Inc. Common Stock was at 11/03/25 10:06 AM ET
What is the market capitalization of NanoViricides, Inc. Common Stock?
The market capitalization of NanoViricides, Inc. Common Stock is 26.90M
How many shares of NanoViricides, Inc. Common Stock are outstanding?
NanoViricides, Inc. Common Stock has 27M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.